Cancer testis antigen (CTA) expression in synovial sarcoma (SS)
| Author | CTA (type) | Method of CTA assessment | Incidence in SS (%) |
| Kakimoto et al42 | NY-ESO-1 | IHC | 59 |
| MAGE-A4 | 53 | ||
| Endo et al44 | NY-ESO-1 | 49 | |
| Lai et al45 | NY-ESO-1 | 82 | |
| Sellner et al *abstract46 | NY-ESO-1 | PCR and IHC | 60 strong + 10 weakly positive |
| Ayyoub et al102 | NY-ESO-1 | PCR and IHC | 100 (n=2) |
| MAGE-A4 | 100 | ||
| Jungbluth et al43 | NY-ESO-1 | IHC | 80 |
| MAGE-A1 | 16 | ||
| CT7 (MAGEC1) | 8 | ||
| Iura et al41 | NY-ESO-1 | PCR and IHC | 61 |
| MAGE-A4 | 82 | ||
| MAGE-A1 | 15 | ||
| PRAME | 86 | ||
| Antonescu et al103 | MAGE-A (unspecified subfamily) | IHC | 88 |
| Jungbluth et al *abstract50 | PRAME | IHC | 100 |
| Luk et al51 | PRAME | PCR | 100 |
| Roszik et al52 | PRAME | Cancer Genome Atlas and Cancer Cell Line Encyclopedia | 100 |
| Segal et al47 | NY-ESO-1 | Microarray | 80 |
| PRAME | 100 | ||
| Guillou et al104 | SYT-SSX | RT-PCR | 96 and 100 (monophasic and biphasic) |
| Wei et al105 | SYT-SSX | RT-PCR | 89 |
IHC, immunohistochemistry; PRAME, Preferentially Expressed Antigen In Melanoma.